Gabriel N Hortobagyi

List of Publications by Year
in descending order

331	46,211	3449 93	2351 205
papers	citations	h-index	g-index

339	339	339	39133
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	A Randomized Trial of Fulvestrant, Everolimus, and Anastrozole for the Front-line Treatment of Patients with Advanced Hormone Receptorâ€“positive Breast Cancer, SWOG S1222. Clinical Cancer Research, 2022, 28, 611-617.	3.2	4
2	Abstract GS2-01: Overall survival subgroup analysis by metastatic site from the phase 3 MONALEESA-2 study of first-line ribociclib + letrozole in postmenopausal patients with advanced HR+/HER2â^' breast cancer. Cancer Research, 2022, 82, GS2-01-GS2-01.	0.4	2
3	Reply to A. Pfob and C. Sidey-Gibbons. JCO Clinical Cancer Informatics, 2022, 6, e2100171.	1.0	0
4	Abstract PD2-05: Genomic profiling of PAM50-based intrinsic subtypes in HR+/HER2- advanced breast cancer (ABC) across the MONALEESA (ML) studies. Cancer Research, 2022, 82, PD2-05-PD2-05.	0.4	2
5	Overall Survival with Ribociclib plus Letrozole in Advanced Breast Cancer. New England Journal of Medicine, 2022, 386, 942-950.	13.9	220
6	Invasive lobular carcinoma: an understudied emergent subtype of breast cancer. Breast Cancer Research and Treatment, 2022, 193, 253-264.	1.1	38
7	Ephrin receptor A10 monoclonal antibodies and the derived chimeric antigen receptor T cells exert an antitumor response in mouse models of triple-negative breast cancer. Journal of Biological Chemistry, 2022, 298, 101817.	1.6	15
8	Molecular Characterization and Prospective Evaluation of Pathologic Response and Outcomes with Neoadjuvant Therapy in Metaplastic Triple-Negative Breast Cancer. Clinical Cancer Research, 2022, 28, 2878-2889.	3.2	10
9	Physical Activity Before, During, and After Chemotherapy for High-Risk Breast Cancer: Relationships With Survival. Journal of the National Cancer Institute, 2021, 113, 54-63.	3.0	98
10	Risk factors for bisphosphonate-associated osteonecrosis of the jaw in the prospective randomized trial of adjuvant bisphosphonates for early-stage breast cancer (SWOG 0307). Supportive Care in Cancer, 2021, 29, 2509-2517.	1.0	17
11	Cellular Fitness Phenotypes of Cancer Target Genes from Oncobiology to Cancer Therapeutics. Cells, 2021, 10, 433.	1.8	5
12	Inflammatory breast cancer: early recognition and diagnosis is critical. American Journal of Obstetrics and Gynecology, 2021, 225, 392-396.	0.7	20
13	TYRO3 induces antiâ€“PD-1/PD-L1 therapy resistance by limiting innate immunity and tumoral ferroptosis. Journal of Clinical Investigation, 2021, 131, .	3.9	135
14	Expanding Criteria for Prognostic Stage IA in Hormone Receptorâ€“Positive Breast Cancer. Journal of the National Cancer Institute, 2021, 113, 1744-1750.	3.0	7
15	Human ribonuclease 1 serves as a secretory ligand of ephrin A4 receptor and induces breast tumor initiation. Nature Communications, 2021, 12, 2788.	5.8	11
16	Association of Cardiovascular Disease Risk Factors with Late Cardiotoxicity and Survival in HER2-positive Breast Cancer Survivors. Clinical Cancer Research, 2021, 27, 5343-5352.	3.2	5
17	Targeting a cell surface vitamin D receptor on tumor-associated macrophages in triple-negative breast cancer. ELife, 2021, 10, .	2.8	18
18	Chemotherapy and Targeted Therapy for Patients With Human Epidermal Growth Factor Receptor 2â€“Negative Metastatic Breast Cancer That is Either Endocrine-Pretreated or Hormone Receptorâ€“Negative: ASCO Guideline Update. Journal of Clinical Oncology, 2021, 39, 3938-3958.	0.8	40

#	Article	IF	Citations
19	Immune Phenotype and Response to Neoadjuvant Therapy in Triple-Negative Breast Cancer. Clinical Cancer Research, 2021, 27, 5365-5375.	3.2	29
20	Prognostic Model for De Novo and Recurrent Metastatic Breast Cancer. JCO Clinical Cancer Informatics, 2021, 5, 789-804.	1.0	10
21	Evaluating Serum Thymidine Kinase 1 in Patients with Hormone Receptorâ€"Positive Metastatic Breast Cancer Receiving First-line Endocrine Therapy in the SWOG S0226 Trial. Clinical Cancer Research, 2021, 27, 6115-6123.	3.2	9
22	Estrogen Receptor: A Paradigm for Targeted Therapy. Cancer Research, 2021, 81, 5396-5398.	0.4	6
23	21-Gene Assay to Inform Chemotherapy Benefit in Node-Positive Breast Cancer. New England Journal of Medicine, 2021, 385, 2336-2347.	13.9	363
24	Phase III Randomized Trial of Bisphosphonates as Adjuvant Therapy in Breast Cancer: S0307. Journal of the National Cancer Institute, 2020, 112, 698-707.	3.0	48
25	Association Between 21-Gene Assay Recurrence Score and Locoregional Recurrence Rates in Patients With Node-Positive Breast Cancer. JAMA Oncology, 2020, 6, 505.	3.4	51
26	Phase II study of Radiumâ€223 dichloride combined with hormonal therapy for hormone receptorâ€positive, boneâ€dominant metastatic breast cancer. Cancer Medicine, 2020, 9, 1025-1032.	1.3	19
27	Dietary Supplement Use During Chemotherapy and Survival Outcomes of Patients With Breast Cancer Enrolled in a Cooperative Group Clinical Trial (SWOG S0221). Journal of Clinical Oncology, 2020, 38, 804-814.	0.8	142
28	Tucatinib, Trastuzumab, and Capecitabine for HER2-Positive Metastatic Breast Cancer. New England Journal of Medicine, 2020, 382, 597-609.	13.9	789
29	Bernard Fisher: A Pioneer Moves On. Oncologist, 2020, 25, 89-90.	1.9	1
30	Cancer Cell Metabolism Bolsters Immunotherapy Resistance by Promoting an Immunosuppressive Tumor Microenvironment. Frontiers in Oncology, 2020, 10, 1197.	1.3	30
31	Validation of Prognostic Stage and Anatomic Stage in the American Joint Committee on Cancer 8th Edition for Inflammatory Breast Cancer. Cancers, 2020, 12, 3105.	1.7	1
32	Impact of Delayed Neoadjuvant Systemic Chemotherapy on Overall Survival Among Patients with Breast Cancer. Oncologist, 2020, 25, 749-757.	1.9	28
33	Incorporation of clinical and biological factors improves prognostication and reflects contemporary clinical practice. Npj Breast Cancer, 2020, 6, 11.	2.3	2
34	Blocking c-Met and EGFR reverses acquired resistance of PARP inhibitors in triple-negative breast cancer. American Journal of Cancer Research, 2020, 10, 648-661.	1.4	15
35	Removal of N-Linked Glycosylation Enhances PD-L1 Detection and Predicts Anti-PD-1/PD-L1 Therapeutic Efficacy. Cancer Cell, 2019, 36, 168-178.e4.	7.7	240
36	Phase II trial of AKT inhibitor MK-2206 in patients with advanced breast cancer who have tumors with PIK3CA or AKT mutations, and/or PTEN loss/PTEN mutation. Breast Cancer Research, 2019, 21, 78.	2.2	141

#	Article	IF	Citations
37	CDK2-mediated site-specific phosphorylation of EZH2 drives and maintains triple-negative breast cancer. Nature Communications, 2019, 10, 5114.	5.8	64
38	Long-Term Survival Analysis of Adjuvant Chemotherapy with or without Trastuzumab in Patients with T1, Node-Negative HER2-Positive Breast Cancer. Clinical Cancer Research, 2019, 25, 7388-7395.	3.2	12
39	Oncogenic lncRNA downregulates cancer cell antigen presentation and intrinsic tumor suppression. Nature Immunology, 2019, 20, 835-851.	7.0	277
40	Overall Survival with Fulvestrant plus Anastrozole in Metastatic Breast Cancer. New England Journal of Medicine, 2019, 380, 1226-1234.	13.9	95
41	Efficacy and Safety of Ribociclib With Letrozole in US Patients Enrolled in the MONALEESA-2 Study. Clinical Breast Cancer, 2019, 19, 268-277.e1.	1.1	13
42	Leptomeningeal carcinomatosis in patients with breast cancer. Critical Reviews in Oncology/Hematology, 2019, 135, 85-94.	2.0	90
43	New and important changes in breast cancer TNM: incorporation of biologic factors into staging. Expert Review of Anticancer Therapy, 2019, 19, 309-318.	1.1	8
44	Circulating Tumor Cell Clusters in Patients with Metastatic Breast Cancer: a SWOG S0500 Translational Medicine Study. Clinical Cancer Research, 2019, 25, 6089-6097.	3.2	46
45	Efficacy and safety of the combination of metformin, everolimus and exemestane in overweight and obese postmenopausal patients with metastatic, hormone receptor-positive, HER2-negative breast cancer: a phase II study. Investigational New Drugs, 2019, 37, 345-351.	1.2	28
46	Indirect Evaluation of Bone Saturation with Zoledronic Acid After Long-Term Dosing. Oncologist, 2019, 24, 178-184.	1.9	4
47	John Mendelsohn: A visionary scientist, oncologist and leader. Genes and Cancer, 2019, 10, 109-118.	0.6	3
48	Synergism of PARP inhibitor fluzoparib (HS10160) and MET inhibitor HS10241 in breast and ovarian cancer cells. American Journal of Cancer Research, 2019, 9, 608-618.	1.4	12
49	Eighth Edition of the AJCC Cancer Staging Manual: Breast Cancer. Annals of Surgical Oncology, 2018, 25, 1783-1785.	0.7	359
50	Development of CNS metastases and survival in patients with inflammatory breast cancer. Cancer, 2018, 124, 2299-2305.	2.0	11
51	A phase II study of tipifarnib and gemcitabine in metastatic breast cancer. Investigational New Drugs, 2018, 36, 299-306.	1.2	16
52	Characterization of bone only metastasis patients with respect to tumor subtypes. Npj Breast Cancer, 2018, 4, 2.	2.3	40
53	Eradication of Triple-Negative Breast Cancer Cells by Targeting Glycosylated PD-L1. Cancer Cell, 2018, 33, 187-201.e10.	7.7	381
54	Ribociclib plus letrozole versus letrozole alone in patients with de novo HR+, HER2â˜’ advanced breast cancer in the randomized MONALEESA-2 trial. Breast Cancer Research and Treatment, 2018, 168, 127-134.	1.1	90

#	Article	IF	Citations
55	Zoledronic Acid Dosing in Patients With Metastatic Breast Cancerâ€"Reply. JAMA Oncology, 2018, 4, 586.	3.4	1
56	Validation Study of the American Joint Committee on Cancer Eighth Edition Prognostic Stage Compared With the Anatomic Stage in Breast Cancer. JAMA Oncology, 2018, 4, 203.	3.4	152
57	New and Important Changes in the TNM Staging System for Breast Cancer. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2018, 38, 457-467.	1.8	83
58	American Society of Clinical Oncologyâ€™s Global Oncology Leadership Task Force: Findings and Actions. Journal of Global Oncology, 2018, 4, 1-8.	0.5	8
59	A phase II study of imatinib mesylate and letrozole in patients with hormone receptor-positive metastatic breast cancer expressing c-kit or PDGFR-Î². Investigational New Drugs, 2018, 36, 1103-1109.	1.2	13
60	Ribociclib for the first-line treatment of advanced hormone receptor-positive breast cancer: a review of subgroup analyses from the MONALEESA-2 trial. Breast Cancer Research, 2018, 20, 123.	2.2	41
61	Adjuvant HER2-Targeted Therapy Update in Breast Cancer: Escalation and De-escalation of Therapy in 2018. Current Breast Cancer Reports, 2018, 10, 296-306.	0.5	5
62	Prognostic Factors in Patients with Metastatic Breast Cancer with Bone-Only Metastases. Oncologist, 2018, 23, 1282-1288.	1.9	46
63	Comparative Effectiveness of an mTOR-Based Systemic Therapy Regimen in Advanced, Metaplastic and Nonmetaplastic Triple-Negative Breast Cancer. Oncologist, 2018, 23, 1300-1309.	1.9	46
64	CDK4/6 inhibitors in hormone receptor-positive, human epidermal growth factor receptor 2 (HER2)-negative metastatic breast cancer: Are we at the finish line?. Oncotarget, 2018, 9, 34193-34195.	0.8	2
65	Ribociclib for HR-Positive, Advanced Breast Cancer. New England Journal of Medicine, 2017, 376, 288-289.	13.9	13
66	Long-Term Prognostic Risk After Neoadjuvant Chemotherapy Associated With Residual Cancer Burden and Breast Cancer Subtype. Journal of Clinical Oncology, 2017, 35, 1049-1060.	0.8	478
67	Continued Treatment Effect of Zoledronic Acid Dosing Every 12 vs 4 Weeks in Women With Breast Cancer Metastatic to Bone. JAMA Oncology, 2017, 3, 906.	3.4	134
68	PARP Inhibitor Upregulates PD-L1 Expression and Enhances Cancer-Associated Immunosuppression. Clinical Cancer Research, 2017, 23, 3711-3720.	3.2	710
69	Correlation between PIK3CA mutations in cell-free DNA and everolimus efficacy in HR+, HER2â^' advanced breast cancer: results from BOLERO-2. British Journal of Cancer, 2017, 116, 726-730.	2.9	112
70	Poor prognosis of patients with triple-negative breast cancer can be stratified by RANK and RANKL dual expression. Breast Cancer Research and Treatment, 2017, 164, 57-67.	1.1	31
71	Personalized Prognostic Prediction Models for Breast Cancer Recurrence and Survival Incorporating Multidimensional Data. Journal of the National Cancer Institute, 2017, 109, .	3.0	42
72	Inflammatory breast cancer: a proposed conceptual shift in the UICCâ€"AJCC TNM staging system. Lancet Oncology, The, 2017, 18, e228-e232.	5.1	74

#	Article	IF	Citations
73	Breast Cancerâ€"Major changes in the American Joint Committee on Cancer eighth edition cancer staging manual. Ca-A Cancer Journal for Clinicians, 2017, 67, 290-303.	157.7	649
74	Cytoplasmic Cyclin E Predicts Recurrence in Patients with Breast Cancer. Clinical Cancer Research, 2017, 23, 2991-3002.	3.2	46
75	Bone metastasis-related signaling pathways in breast cancers stratified by estrogen receptor status. Journal of Cancer, 2017, 8, 1045-1052.	1.2	9
76	Circulating tumor cells (CTCs) are associated with abnormalities in peripheral blood dendritic cells in patients with inflammatory breast cancer. Oncotarget, 2017, 8, 35656-35668.	0.8	44
77	EGFR signaling promotes inflammation and cancer stem-like activity in inflammatory breast cancer. Oncotarget, 2017, 8, 67904-67917.	0.8	40
78	Reverse phase protein array identification of triple-negative breast cancer subtypes and comparison with mRNA molecular subtypes. Oncotarget, 2017, 8, 70481-70495.	0.8	14
79	The Association between EGFR and cMET Expression and Phosphorylation and Its Prognostic Implication in Patients with Breast Cancer. PLoS ONE, 2016, 11, e0152585.	1.1	14
80	Current challenges of metastatic breast cancer. Cancer and Metastasis Reviews, 2016, 35, 495-514.	2.7	63
81	High HER2/Centromeric Probe for Chromosome 17 Fluorescence In Situ Hybridization Ratio Predicts Pathologic Complete Response and Survival Outcome in Patients Receiving Neoadjuvant Systemic Therapy With Trastuzumab for HER2-Overexpressing Locally Advanced Breast Cancer. Oncologist, 2016, 21, 21-27.	1.9	19
82	Ribociclib as First-Line Therapy for HR-Positive, Advanced Breast Cancer. New England Journal of Medicine, 2016, 375, 1738-1748.	13.9	1,390
83	Prevalence of ESR1 Mutations in Cell-Free DNA and Outcomes in Metastatic Breast Cancer. JAMA Oncology, 2016, 2, 1310.	3.4	395
84	Glycosylation and stabilization of programmed death ligand-1 suppresses T-cell activity. Nature Communications, 2016, 7, 12632.	5.8	648
85	Deubiquitination and Stabilization of PD-L1 by CSN5. Cancer Cell, 2016, 30, 925-939.	7.7	538
86	Towards a transcriptome-based theranostic platform for unfavorable breast cancer phenotypes. Proceedings of the National Academy of Sciences of the United States of America, 2016, 113, 12780-12785.	3.3	31
87	Phase I biomarker modulation study of atorvastatin in women at increased risk for breast cancer. Breast Cancer Research and Treatment, 2016, 158, 67-77.	1.1	16
88	Incidence of Atypical Femur Fractures in Cancer Patients: The MD Anderson Cancer Center Experience. Journal of Bone and Mineral Research, 2016, 31, 1569-1576.	3.1	44
89	AKT1 Inhibits Epithelial-to-Mesenchymal Transition in Breast Cancer through Phosphorylation-Dependent Twist1 Degradation. Cancer Research, 2016, 76, 1451-1462.	0.4	65
90	EGFR Signaling Enhances Aerobic Glycolysis in Triple-Negative Breast Cancer Cells to Promote Tumor Growth and Immune Escape. Cancer Research, 2016, 76, 1284-1296.	0.4	190

#	Article	IF	Citations
91	Blocking c-Metâ€“mediated PARP1 phosphorylation enhances anti-tumor effects of PARP inhibitors. Nature Medicine, 2016, 22, 194-201.	15.2	189
92	The American Society of Clinical Oncology's Efforts to Support Global Cancer Medicine. Journal of Clinical Oncology, 2016, 34, 76-82.	0.8	13
93	The Neo-Bioscore Update for Staging Breast Cancer Treated With Neoadjuvant Chemotherapy. JAMA Oncology, 2016, 2, 929.	3.4	94
94	Ten-Year Outcomes of Patients With Breast Cancer With Cytologically Confirmed Axillary Lymph Node Metastases and Pathologic Complete Response After Primary Systemic Chemotherapy. JAMA Oncology, 2016, 2, 508.	3.4	103
95	Correlative Analysis of Genetic Alterations and Everolimus Benefit in Hormone Receptorâ€“Positive, Human Epidermal Growth Factor Receptor 2â€“Negative Advanced Breast Cancer: Results From BOLERO-2. Journal of Clinical Oncology, 2016, 34, 419-426.	0.8	203
96	Association of Body Mass Index Changes during Neoadjuvant Chemotherapy with Pathologic Complete Response and Clinical Outcomes in Patients with Locally Advanced Breast Cancer. Journal of Cancer, 2015, 6, 310-318.	1.2	20
97	Phase II Randomized Study of Ixabepilone Versus Observation in Patients With Significant Residual Disease After Neoadjuvant Systemic Therapy for HER2-Negative Breast Cancer. Clinical Breast Cancer, 2015, 15, 325-331.	1.1	18
98	The PARP inhibitor AZD2281 (Olaparib) induces autophagy/mitophagy in BRCA1 and BRCA2 mutant breast cancer cells. International Journal of Oncology, 2015, 47, 262-268.	1.4	81
99	Circulating tumor cells in newly diagnosed inflammatory breast cancer. Breast Cancer Research, 2015, 17, 2.	2.2	36
100	Effect of 21-Gene RT-PCR Assay on Adjuvant Therapy and Outcomes in Patients With Stage I Breast Cancer. Clinical Breast Cancer, 2015, 15, 458-466.	1.1	10
101	Acute and Short-term Toxic Effects of Conventionally Fractionated vs Hypofractionated Whole-Breast Irradiation. JAMA Oncology, 2015, 1, 931.	3.4	216
102	BRCAPRO 6.0 Model Validation in Male Patients Presenting for BRCA Testing. Oncologist, 2015, 20, 593-597.	1.9	13
103	Everolimus Plus Exemestane for the Treatment of Advanced Breast Cancer: A Review of Subanalyses from BOLERO-2. Neoplasia, 2015, 17, 279-288.	2.3	56
104	Receptor Status Change From Primary to Residual Breast Cancer After Neoadjuvant Chemotherapy and Analysis of Survival Outcomes. Clinical Breast Cancer, 2015, 15, 153-160.	1.1	33
105	Antitumor Activity of KW-2450 against Triple-Negative Breast Cancer by Inhibiting Aurora A and B Kinases. Molecular Cancer Therapeutics, 2015, 14, 2687-2699.	1.9	15
106	Comparison of cardiac events associated with liposomal doxorubicin, epirubicin and doxorubicin in breast cancer: a Bayesian network meta-analysis. European Journal of Cancer, 2015, 51, 2314-2320.	1.3	58
107	SWOG S0221: A Phase III Trial Comparing Chemotherapy Schedules in High-Risk Early-Stage Breast Cancer. Journal of Clinical Oncology, 2015, 33, 58-64.	0.8	89
108	Phase III trial of bisphosphonates as adjuvant therapy in primary breast cancer: SWOG/Alliance/ECOG-ACRIN/NCIC Clinical Trials Group/NRG Oncology study S0307.. Journal of Clinical Oncology, 2015, 33, 503-503.	0.8	16

#	Article	IF	Citations
109	Functional consequence of theMET-T1010I polymorphism in breast cancer. Oncotarget, 2015, 6, 2604-2614.	0.8	34
110	Phosphorylation of EZH2 at T416 by CDK2 contributes to the malignancy of triple negative breast cancers. American Journal of Translational Research (discontinued), 2015, 7, 1009-20.	0.0	28
111	High Serum miR-19a Levels Are Associated with Inflammatory Breast Cancer and Are Predictive of Favorable Clinical Outcome in Patients with Metastatic HER2+ Inflammatory Breast Cancer. PLoS ONE, 2014, 9, e83113.	1.1	91
112	cMET Activation and EGFR-Directed Therapy Resistance in Triple-Negative Breast Cancer. Journal of Cancer, 2014, 5, 745-753.	1.2	46
113	Breast Cancer, BRCA Mutations, and Attitudes Regarding Pregnancy and Preimplantation Genetic Diagnosis. Oncologist, 2014, 19, 797-804.	1.9	21
114	Gene Signatureâ€"Guided Dasatinib Therapy in Metastatic Breast Cancer. Clinical Cancer Research, 2014, 20, 5265-5271.	3.2	28
115	Outcomes of children exposed in uteroto chemotherapy for breast cancer. Breast Cancer Research, 2014, 16, 500.	2.2	75
116	Reverse-Phase Protein Array for Prediction of Patients at Low Risk of Developing Bone Metastasis From Breast Cancer. Oncologist, 2014, 19, 909-914.	1.9	15
117	TP53 mutationâ€correlated genes predict the risk of tumor relapse and identify MPS1 as a potential therapeutic kinase in TP53â€mutated breast cancers. Molecular Oncology, 2014, 8, 508-519.	2.1	59
118	Effect of Age and Race On Quality of Life in Young Breast Cancer Survivors. Clinical Breast Cancer, 2014, 14, e21-e31.	1.1	42
119	Everolimus plus exemestane as first-line therapy in HR+, HER2â^' advanced breast cancer in BOLERO-2. Breast Cancer Research and Treatment, 2014, 143, 459-467.	1.1	74
120	Simvastatin Radiosensitizes Differentiated and Stem-Like Breast Cancer Cell Lines and Is Associated With Improved Local Control in Inflammatory Breast Cancer Patients Treated With Postmastectomy Radiation. Stem Cells Translational Medicine, 2014, 3, 849-856.	1.6	69
121	Chemotherapy and Targeted Therapy for Women With Human Epidermal Growth Factor Receptor 2â€"Negative (or unknown) Advanced Breast Cancer: American Society of Clinical Oncology Clinical Practice Guideline. Journal of Clinical Oncology, 2014, 32, 3307-3329.	0.8	210
122	Circulating Tumor Cells and Response to Chemotherapy in Metastatic Breast Cancer: SWOG S0500. Journal of Clinical Oncology, 2014, 32, 3483-3489.	0.8	543
123	Definition of PKC-Î±, CDK6, and MET as Therapeutic Targets in Triple-Negative Breast Cancer. Cancer Research, 2014, 74, 4822-4835.	0.4	61
124	Locoregional Recurrence Risk for Patients With T1,2 Breast Cancer With 1-3 Positive Lymph Nodes Treated With Mastectomy and Systemic Treatment. International Journal of Radiation Oncology Biology Physics, 2014, 89, 392-398.	0.4	126
125	Safety and Efficacy of Everolimus With Exemestane vs. Exemestane Alone in Elderly Patients With HER2-Negative, Hormone Receptorâ€"Positive Breast Cancer in BOLERO-2. Clinical Breast Cancer, 2013, 13, 421-432.e8.	1.1	104
126	Effect of Everolimus on Bone Marker Levels and Progressive Disease in Bone in BOLERO-2. Journal of the National Cancer Institute, 2013, 105, 654-663.	3.0	88

#	Article	IF	Citations
127	Everolimus Plus Exemestane in Postmenopausal Patients with HR+ Breast Cancer: BOLERO-2 Final Progression-Free Survival Analysis. Advances in Therapy, 2013, 30, 870-884.	1.3	430
128	Healthâ€related quality of life of patients with advanced breast cancer treated with everolimus plus exemestane versus placebo plus exemestane in the phase 3, randomized, controlled, BOLEROâ€2 trial. Cancer, 2013, 119, 1908-1915.	2.0	81
129	Supplement use during an intergroup clinical trial for breast cancer (S0221). Breast Cancer Research and Treatment, 2013, 137, 903-913.	1.1	31
130	Effect of visceral metastases on the efficacy and safety of everolimus in postmenopausal women with advanced breast cancer: Subgroup analysis from the BOLERO-2 study. European Journal of Cancer, 2013, 49, 2621-2632.	1.3	53
131	Case Control Study of Women Treated With Chemotherapy for Breast Cancer During Pregnancy as Compared With Nonpregnant Patients With Breast Cancer. Oncologist, 2013, 18, 369-376.	1.9	74
132	Health-related quality of life and disease symptoms in postmenopausal women with HR⁺, HER2^{â^'}advanced breast cancer treated with everolimus plus exemestane versus exemestane monotherapy. Current Medical Research and Opinion, 2013, 29, 1463-1473.	0.9	24
133	Differential Response to Neoadjuvant Chemotherapy Among 7 Triple-Negative Breast Cancer Molecular Subtypes. Clinical Cancer Research, 2013, 19, 5533-5540.	3.2	597
134	Incidence, management, and resolution of noninfectious pneumonitis in BOLERO-2.. Journal of Clinical Oncology, 2013, 31, 561-561.	0.8	5
135	Correlation of molecular alterations with efficacy of everolimus in hormone receptorâ€“positive, HER2-negative advanced breast cancer: Results from BOLERO-2.. Journal of Clinical Oncology, 2013, 31, LBA509-LBA509.	0.8	49
136	Correlation of molecular alterations with efficacy of everolimus in hormone-receptorâ€“positive (HR+), HER2-negative advanced breast cancer: Preliminary results from BOLERO-2.. Journal of Clinical Oncology, 2013, 31, LBA509-LBA509.	0.8	10
137	Toward Individualized Breast Cancer Therapy: Translating Biological Concepts to the Bedside. Oncologist, 2012, 17, 577-584.	1.9	17
138	Everolimus in Postmenopausal Hormone-Receptorâ€“Positive Advanced Breast Cancer. New England Journal of Medicine, 2012, 366, 520-529.	13.9	2,474
139	Combination Anastrozole and Fulvestrant in Metastatic Breast Cancer. New England Journal of Medicine, 2012, 367, 435-444.	13.9	352
140	Survival outcomes in HER2-positive invasive lobular breast carcinoma.. Journal of Clinical Oncology, 2012, 30, 612-612.	0.8	2
141	Circulating tumor cells as prognostic and predictive markers in metastatic breast cancer patients receiving first-line systemic treatment. Breast Cancer Research, 2011, 13, R67.	2.2	188
142	First generation prognostic gene signatures for breast cancer predict both survival and chemotherapy sensitivity and identify overlapping patient populations. Breast Cancer Research and Treatment, 2011, 130, 155-164.	1.1	36
143	Gene Pathways Associated With Prognosis and Chemotherapy Sensitivity in Molecular Subtypes of Breast Cancer. Journal of the National Cancer Institute, 2011, 103, 264-272.	3.0	203
144	High-Dose Chemotherapy With Autologous Stem-Cell Support As Adjuvant Therapy in Breast Cancer: Overview of 15 Randomized Trials. Journal of Clinical Oncology, 2011, 29, 3214-3223.	0.8	89

#	Article	IF	Citations
145	Novel Staging System for Predicting Disease-Specific Survival in Patients With Breast Cancer Treated With Surgery As the First Intervention: Time to Modify the Current American Joint Committee on Cancer Staging System. Journal of Clinical Oncology, 2011, 29, 4654-4661.	0.8	92
146	Phase I/II Study of Trastuzumab in Combination With Everolimus (RAD001) in Patients With HER2-Overexpressing Metastatic Breast Cancer Who Progressed on Trastuzumab-Based Therapy. Journal of Clinical Oncology, 2011, 29, 3126-3132.	0.8	207
147	PI3K Pathway Mutations and PTEN Levels in Primary and Metastatic Breast Cancer. Molecular Cancer Therapeutics, 2011, 10, 1093-1101.	1.9	204
148	Analysis of overall survival from a phase III study of ixabepilone plus capecitabine versus capecitabine in patients with MBC resistant to anthracyclines and taxanes. Breast Cancer Research and Treatment, 2010, 122, 409-418.	1.1	65
149	Primary systemic therapy for operable breast cancer patients: the need for the new generation of trial design. Breast Cancer Research and Treatment, 2010, 124, 701-705.	1.1	2
150	A phase 2 study of a fixed combination of uracil and ftorafur (UFT) and leucovorin given orally in a 3-times-daily regimen to treat patients with recurrent metastatic breast cancer. Cancer, 2010, 116, 1440-1445.	2.0	5
151	Phase 2 trial of primary systemic therapy with doxorubicin and docetaxel followed by surgery, radiotherapy, and adjuvant chemotherapy with cyclophosphamide, methotrexate, and 5â€fluorouracil based on clinical and pathologic response in patients with stage IIB to III breast cancer. Cancer, 2010, 116, 1210-1217.	2.0	11
152	A phase 2 study of a fixed combination of uracil and ftorafur and leucovorin given orally in a twice-daily regimen to treat patients with recurrent metastatic breast cancer. Cancer, 2010, 116, NA-NA.	2.0	4
153	Circulating Tumor Cells and Biomarkers: Implications for Personalized Targeted Treatments for Metastatic Breast Cancer. Breast Journal, 2010, 16, 327-330.	0.4	32
154	Estrogen Receptor Expression and Docetaxel Efficacy in Patients with Metastatic Breast Cancer: A Pooled Analysis of Four Randomized Trials. Oncologist, 2010, 15, 476-483.	1.9	6
155	Predictors of Tumor Progression During Neoadjuvant Chemotherapy in Breast Cancer. Journal of Clinical Oncology, 2010, 28, 1821-1828.	0.8	128
156	Two Good Choices to Prevent Breast Cancer: Great Taste, Less Filling. Cancer Prevention Research, 2010, 3, 681-685.	0.7	15
157	Prognosis of Women With Metastatic Breast Cancer by HER2 Status and Trastuzumab Treatment: An Institutional-Based Review. Journal of Clinical Oncology, 2010, 28, 92-98.	0.8	666
158	Future directions of bone-targeted therapy for metastatic breast cancer. Nature Reviews Clinical Oncology, 2010, 7, 641-651.	12.5	97
159	Prognostic and predictive value of the 21-gene recurrence score assay in postmenopausal women with node-positive, oestrogen-receptor-positive breast cancer on chemotherapy: a retrospective analysis of a randomised trial. Lancet Oncology, The, 2010, 11, 55-65.	5.1	1,252
160	Molecular predictors of response to trastuzumab and lapatinib in breast cancer. Nature Reviews Clinical Oncology, 2010, 7, 98-107.	12.5	148
161	Why my neighbor's health is important to me. Oncology, 2010, 24, 1238.	0.4	0
162	Characterization of a Naturally Occurring Breast Cancer Subset Enriched in Epithelial-to-Mesenchymal Transition and Stem Cell Characteristics. Cancer Research, 2009, 69, 4116-4124.	0.4	768

#	Article	IF	Citations
163	Circulating Tumor Cells and [¹⁸F]Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography for Outcome Prediction in Metastatic Breast Cancer. Journal of Clinical Oncology, 2009, 27, 3303-3311.	0.8	139
164	Molecular targets for treatment of inflammatory breast cancer. Nature Reviews Clinical Oncology, 2009, 6, 387-394.	12.5	52
165	The HER-2 Receptor and Breast Cancer: Ten Years of Targeted Antiâ€“HER-2 Therapy and Personalized Medicine. Oncologist, 2009, 14, 320-368.	1.9	986
166	A time for creative collaboration. Cancer, 2008, 113, 2217-2220.	2.0	2
167	Locally advanced breast cancer. Cancer, 2008, 113, 2315-2324.	2.0	45
168	Circulating tumor cells in metastatic breast cancer. Cancer, 2008, 113, 2422-2430.	2.0	156
169	Fingerprinting Lymph Node Metastases. Annals of Surgical Oncology, 2008, 15, 1275-1276.	0.7	0
170	ERK promotes tumorigenesis by inhibiting FOXO3a via MDM2-mediated degradation. Nature Cell Biology, 2008, 10, 138-148.	4.6	590
171	Using Response to Primary Chemotherapy to Select Postoperative Therapy: Long-Term Results from a Prospective Phase II Trial in Locally Advanced Primary Breast Cancer. Clinical Breast Cancer, 2008, 8, 516-521.	1.1	11
172	Response to Neoadjuvant Therapy and Long-Term Survival in Patients With Triple-Negative Breast Cancer. Journal of Clinical Oncology, 2008, 26, 1275-1281.	0.8	2,387
173	Commercialized Multigene Predictors of Clinical Outcome for Breast Cancer. Oncologist, 2008, 13, 477-493.	1.9	235
174	Staging of Breast Cancer in the Neoadjuvant Setting. Cancer Research, 2008, 68, 6477-6481.	0.4	38
175	Residual Ductal Carcinoma In Situ in Patients With Complete Eradication of Invasive Breast Cancer After Neoadjuvant Chemotherapy Does Not Adversely Affect Patient Outcome. Journal of Clinical Oncology, 2007, 25, 2650-2655.	0.8	253
176	A Shortage of Oncologists? The American Society of Clinical Oncology Workforce Study. Journal of Clinical Oncology, 2007, 25, 1468-1469.	0.8	73
177	Overall Survival and Cause-Specific Mortality of Patients With Stage T1a,bN0M0 Breast Carcinoma. Journal of Clinical Oncology, 2007, 25, 4952-4960.	0.8	258
178	IKKÎ² Suppression of TSC1 Links Inflammation and Tumor Angiogenesis via the mTOR Pathway. Cell, 2007, 130, 440-455.	13.5	585
179	Measurement of Residual Breast Cancer Burden to Predict Survival After Neoadjuvant Chemotherapy. Journal of Clinical Oncology, 2007, 25, 4414-4422.	0.8	1,243
180	Circulating Tumor Cells in Metastatic Breast Cancer: Biologic Staging Beyond Tumor Burden. Clinical Breast Cancer, 2007, 7, 34-42.	1.1	141

#	Article	IF	Citations
181	Inflammatory breast cancer (IBC) and patterns of recurrence. Cancer, 2007, 110, 1436-1444.	2.0	194
182	Clinicopathologic characteristics and prognostic factors in 420 metastatic breast cancer patients with central nervous system metastasis. Cancer, 2007, 110, 2640-2647.	2.0	147
183	Circulating tumor cells in metastatic breast cancer: biologic staging beyond tumor burden. Clinical Breast Cancer, 2007, 7, 471-9.	1.1	67
184	Personalized medicine for breast cancer: moving forward and going back. Personalized Medicine, 2006, 3, 363-370.	0.8	1
185	Randomized trial of high-dose chemotherapy and autologous hematopoietic stem cell support for high-risk primary breast carcinoma. Cancer, 2006, 106, 2327-2336.	2.0	26
186	Treatment of pregnant breast cancer patients and outcomes of children exposed to chemotherapy in utero. Cancer, 2006, 107, 1219-1226.	2.0	342
187	Long-Term Cardiac Tolerability of Trastuzumab in Metastatic Breast Cancer: The M.D. Anderson Cancer Center Experience. Journal of Clinical Oncology, 2006, 24, 4107-4115.	0.8	336
188	The natural history of breast carcinoma in patients with â‰¥ 10 metastatic axillary lymph nodes before and after the advent of adjuvant therapy. Cancer, 2005, 104, 229-235.	2.0	27
189	Invasive Lobular Carcinoma Classic Type: Response to Primary Chemotherapy and Survival Outcomes. Journal of Clinical Oncology, 2005, 23, 41-48.	0.8	352
190	Significantly Higher Pathologic Complete Remission Rate After Neoadjuvant Therapy With Trastuzumab, Paclitaxel, and Epirubicin Chemotherapy: Results of a Randomized Trial in Human Epidermal Growth Factor Receptor 2â€“Positive Operable Breast Cancer. Journal of Clinical Oncology, 2005, 23, 3676-3685.	0.8	1,076
191	Outcome After Pathologic Complete Eradication of Cytologically Proven Breast Cancer Axillary Node Metastases Following Primary Chemotherapy. Journal of Clinical Oncology, 2005, 23, 9304-9311.	0.8	366
192	Chemotherapy: What Progress in the Last 5 Years?. Journal of Clinical Oncology, 2005, 23, 1760-1775.	0.8	96
193	Circulating Tumor Cells: A Novel Prognostic Factor for Newly Diagnosed Metastatic Breast Cancer. Journal of Clinical Oncology, 2005, 23, 1420-1430.	0.8	1,012
194	Moving into the future: Treatment of bone metastases and beyond. Cancer Treatment Reviews, 2005, 31, 9-18.	3.4	18
195	The Global Breast Cancer Burden: Variations in Epidemiology and Survival. Clinical Breast Cancer, 2005, 6, 391-401.	1.1	445
196	The Use of Alternate, Nonâ€“Cross-Resistant Adjuvant Chemotherapy on the Basis of Pathologic Response to a Neoadjuvant Doxorubicin-Based Regimen in Women With Operable Breast Cancer: Long-Term Results From a Prospective Randomized Trial. Journal of Clinical Oncology, 2004, 22, 2294-2302.	0.8	137
197	Inflammatory Breast Carcinoma: The Sphinx of Breast Cancer Research. Journal of Clinical Oncology, 2004, 22, 381-383.	0.8	38
198	Opportunities and challenges in the development of targeted therapies. Seminars in Oncology, 2004, 31, 21-27.	0.8	33

#	Article	IF	Citations
199	PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients. Cancer Cell, 2004, 6, 117-127.	7.7	1,693
200	Is breast cancer survival improving?. Cancer, 2004, 100, 44-52.	2.0	469
201	Prognostic value of P53, MDM-2, and MUC-1 for patients with inflammatory breast carcinoma. Cancer, 2004, 101, 913-917.	2.0	17
202	Targeted Radiotherapy to the Skeleton Using 166Ho-DOTMP with Autologous Stem Cell Transplantation for Patients with Bone-Only Metastatic Breast Cancer.. Blood, 2004, 104, 5239-5239.	0.6	1
203	New Approaches to Breast Cancer Therapy. Breast Cancer Research and Treatment, 2003, 80, 1-2.	1.1	23
204	Future Directions in the Endocrine Therapy of Breast Cancer. Breast Cancer Research and Treatment, 2003, 80, 37-39.	1.1	4
205	Novel approaches to the management of bone metastases. Seminars in Oncology, 2003, 30, 161-166.	0.8	8
206	Update on the Management of Inflammatory Breast Cancer. Oncologist, 2003, 8, 141-148.	1.9	126
207	Gemcitabine in Combination with Vinorelbine for Treatment of Advanced Breast Cancer. Clinical Breast Cancer, 2002, 3, S34-S38.	1.1	8
208	The Status of Breast Cancer Management: Challenges and Opportunities. Breast Cancer Research and Treatment, 2002, 75, 61-65.	1.1	13
209	Novel approaches to the management of bone metastases in patients with breast cancer. Seminars in Oncology, 2002, 29, 134-144.	0.8	36
210	Long-term complications associated with breast-conservation surgery and radiotherapy. , 2002, 9, 543.		12
211	Integration of docetaxel into adjuvant breast cancer treatment regimens. Oncology, 2002, 16, 27-33.	0.4	0
212	Long-Term Results of Combined-Modality Therapy for Locally Advanced Breast Cancer With Ipsilateral Supraclavicular Metastases: The University of Texas M.D. Anderson Cancer Center Experience. Journal of Clinical Oncology, 2001, 19, 628-633.	0.8	200
213	Progress in Systemic Chemotherapy of Primary Breast Cancer: an Overview. Journal of the National Cancer Institute Monographs, 2001, 2001, 72-79.	0.9	39
214	Expression of erbB/HER receptors, heregulin and p38 in primary breast cancer using quantitative immunohistochemistry. Pathology and Oncology Research, 2001, 7, 171-177.	0.9	56
215	Phase I study of vinorelbine and paclitaxel by 3-hour simultaneous infusion with and without granulocyte colony-stimulating factor support in metastatic breast carcinoma. Cancer, 2001, 91, 664-671.	2.0	10
216	Breast conservation therapy as a treatment option for the elderly. Cancer, 2001, 92, 1092-1100.	2.0	50

#	Article	IF	Citations
217	Female patients with breast carcinoma age 30 years and younger have a poor prognosis. Cancer, 2001, 92, 2523-2528.	2.0	154
218	Phase Iâ€“II Vinorelbine (NavelbineÂ®) by Continuous Infusion in Patients with Metastatic Breast Cancer: Cumulative Toxicities Limit Dose Escalation. Cancer Investigation, 2001, 19, 459-466.	0.6	7
219	Canalicular Stenosis as the Underlying Mechanism for Epiphora in Patients Receiving Weekly Docetaxel. Oncologist, 2001, 6, 551-552.	1.9	26
220	Female patients with breast carcinoma age 30 years and younger have a poor prognosis. , 2001, 92, 2523.		1
221	The evolving role of bisphosphonates. Seminars in Oncology, 2001, 28, 284-290.	0.8	19
222	Overview of treatment results with trastuzumab (Herceptin) in metastatic breast cancer. Seminars in Oncology, 2001, 28, 43-47.	0.8	76
223	Oral bisphosphonates. Cancer, 2000, 88, 6-14.	2.0	124
224	Pamidronate prevents skeletal complications and is effective palliative treatment in women with breast carcinoma and osteolytic bone metastases. , 2000, 88, 1082-1090.		592
225	Combined modality treatment of locally advanced breast carcinoma in elderly patients or patients with severe comorbid conditions using tamoxifen as the primary therapy. , 2000, 88, 2054-2060.		35
226	Developments in chemotherapy of breast cancer. Cancer, 2000, 88, 3073-3079.	2.0	82
227	Phase II study of paclitaxel in patients with metastatic breast carcinoma refractory to standard chemotherapy. Cancer, 2000, 89, 2195-2201.	2.0	21
228	Phase II trial and pharmacokinetic evaluation of cytosine arabinoside for leptomeningeal metastases from breast cancer. Cancer Chemotherapy and Pharmacology, 2000, 46, 382-386.	1.1	36
229	Phase I study of liposomal annamycin. Cancer Chemotherapy and Pharmacology, 2000, 46, 427-432.	1.1	14
230	Prognostic Implications of Pathological Lymph Node Status After Preoperative Chemotherapy for Operable T3N0M0 Breast Cancer. Annals of Surgical Oncology, 2000, 7, 435-440.	0.7	26
231	Ductal Carcinoma-In-Situ: Long-Term Results of Breast-Conserving Therapy. Annals of Surgical Oncology, 2000, 7, 656-664.	0.7	38
232	Randomized Trial of High-Dose Chemotherapy and Blood Cell Autografts for High-Risk Primary Breast Carcinoma. Journal of the National Cancer Institute, 2000, 92, 225-233.	3.0	161
233	Risks and Benefits of Taxanes in Breast and Ovarian Cancer. Drug Safety, 2000, 23, 401-428.	1.4	97
234	Phase II Trial of Liposome-Encapsulated Doxorubicin, Cyclophosphamide, and Fluorouracil as First-Line Therapy in Patients With Metastatic Breast Cancer. Journal of Clinical Oncology, 1999, 17, 1425-1425.	0.8	86

#	Article	IF	Citations
235	Prospective Evaluation of Paclitaxel Versus Combination Chemotherapy With Fluorouracil, Doxorubicin, and Cyclophosphamide as Neoadjuvant Therapy in Patients With Operable Breast Cancer. Journal of Clinical Oncology, 1999, 17, 3412-3417.	0.8	234
236	Pamidronate Reduces Skeletal Morbidity in Women With Advanced Breast Cancer and Lytic Bone Lesions: A Randomized, Placebo-Controlled Trial. Journal of Clinical Oncology, 1999, 17, 846-846.	0.8	597
237	Management of Breast Cancer During Pregnancy Using a Standardized Protocol. Journal of Clinical Oncology, 1999, 17, 855-855.	0.8	400
238	Phase I/II trial of high dose mitoxantrone in metastatic breast cancer: the M.D. Anderson Cancer Center experience. Breast Cancer Research and Treatment, 1999, 54, 225-233.	1.1	13
239	Relapse after complete response to anthracyclineâ€based combination chemotherapy in metastatic breast cancer. Breast Cancer Research and Treatment, 1999, 55, 1-8.	1.1	4
240	Phase II study of mitoxantrone by 14-day continuous infusion with granulocyte colony-stimulating factor (GCSF) support in patients with metastatic breast cancer and limited prior therapy. Cancer Chemotherapy and Pharmacology, 1999, 43, 86-91.	1.1	2
241	Doxorubicin-induced congestive heart failure in elderly patients with metastatic breast cancer, with long-term follow-up: the M.D. Anderson experience. Cancer Chemotherapy and Pharmacology, 1999, 43, 471-478.	1.1	51
242	Primary Tumor Response to Induction Chemotherapy as a Predictor of Histological Status of Axillary Nodes in Operable Breast Cancer Patients. Annals of Surgical Oncology, 1999, 6, 762-767.	0.7	31
243	Results and long term follow-up for 1581 patients with metastatic breast carcinoma treated with standard dose doxorubicin-containing chemotherapy. , 1999, 85, 104-111.		118
244	Phase II study of vinorelbine administered by 96-hour infusion in patients with advanced breast carcinoma. , 1999, 86, 1251-1257.		20
245	Clinical Course of Breast Cancer Patients With Complete Pathologic Primary Tumor and Axillary Lymph Node Response to Doxorubicin-Based Neoadjuvant Chemotherapy. Journal of Clinical Oncology, 1999, 17, 460-460.	0.8	1,199
246	Overexpression of both p185c-erbB2 and p170mdr-1 renders breast cancer cells highly resistant to taxol. Oncogene, 1998, 16, 2087-2094.	2.6	122
247	Tyrosine kinase inhibitors, emodin and its derivative repress HER-2/neu-induced cellular transformation and metastasis-associated properties. Oncogene, 1998, 16, 2855-2863.	2.6	108
248	Hand-foot syndrome following prolonged infusion of high doses of vinorelbine. , 1998, 82, 965-969.		43
249	Progress in endocrine therapy for breast carcinoma. , 1998, 83, 1-6.		11
250	Role of axillary lymph node dissection after tumor downstaging with induction chemotherapy for locally advanced breast cancer. Annals of Surgical Oncology, 1998, 5, 673-680.	0.7	72
251	New Antiestrogens in Breast Cancer: A Review. Breast Journal, 1998, 4, 213-229.	0.4	3
252	Residual metastatic axillary lymph nodes following neoadjuvant chemotherapy predict disease-free survival in patients with locally advanced breast cancer. American Journal of Surgery, 1998, 176, 502-509.	0.9	149

#	Article	IF	Citations
253	Treatment of Breast Cancer. New England Journal of Medicine, 1998, 339, 974-984.	13.9	695
254	Anastrozole (ArimidexÂ®), a New Aromatase Inhibitor for Advanced Breast Cancer: Mechanism of Action and Role in Management. Cancer Investigation, 1998, 16, 385-390.	0.6	5
255	Integration of Systemic Chemotherapy in the Management of Primary Breast Cancer. Oncologist, 1998, 3, 300-313.	1.9	17
256	Paclitaxel-Induced Pancreatitis: A Case Report. Journal of the National Cancer Institute, 1997, 89, 91-93.	3.0	16
257	The tumor suppression activity of E1A in HER-2/neu-overexpressing breast cancer. Oncogene, 1997, 14, 561-568.	2.6	81
258	Anthracycline-resistant breast cancer. Breast Cancer, 1997, 4, 221-227.	1.3	2
259	Combined-modality treatment of inflammatory breast carcinoma: twenty years of experience at M. D. Anderson Cancer Center. Cancer Chemotherapy and Pharmacology, 1997, 40, 321-329.	1.1	242
260	Chemotherapy-induced neutropenia and fever in patients with metastatic breast carcinoma receiving salvage chemotherapy. , 1997, 79, 1150-1157.		32
261	The prognostic significance of sialyl-tn Antigen in women treated with breast carcinoma treated with adjuvant chemotherapy. , 1997, 80, 2240-2249.		41
262	Secondary drug resistance in breast cancer: Failure to reverse with oral nifedipine. , 1997, 73, 184-186.		4
263	A phase II study of CI-973 [SP-4-3(R)]- [1, 1-cyclobutane-dicarboxylato (2-)] (2-methyl-1,4-butanediamine-N,) Tj ETQq1 1 0.784314 rgBT Pharmacology, 1996, 38, 289-291.	1.1	8
264	Technical approach for the study of the genetic evolution of breast cancer from paraffin-embedded tissue sections. Breast Cancer Research and Treatment, 1996, 39, 177-185.	1.1	11
265	Locally Advanced Breast Cancer. Oncologist, 1996, 1, 8-17.	1.9	85
266	Current status of adjuvant systemic therapy for primary breast cancer: progress and controversy. Ca-A Cancer Journal for Clinicians, 1995, 45, 199-226.	157.7	59
267	Factors predicting long-term survival for metastatic breast cancer patients treated with high-dose chemotherapy and bone marrow support. Cancer, 1994, 73, 2157-2167.	2.0	97
268	Multidisciplinary management of advanced primary and metastatic breast cancer. Cancer, 1994, 74, 416-423.	2.0	115
269	Phase I trail of droloxifene in patients with metastatic breast cancer. Cancer Chemotherapy and Pharmacology, 1994, 33, 313-316.	1.1	31
270	Anthracycline Antibiotics in Cancer Therapy. Drugs, 1994, 47, 223-258.	4.9	170

#	Article	IF	Citations
271	Phase I trial of droloxifene in patients with metastatic breast cancer. Cancer Chemotherapy and Pharmacology, 1994, 33, 313-316.	1.1	1
272	The order of administration of chemotherapy and radiation and its effect on the local control of operable breast cancer. Cancer, 1993, 71, 3680-3684.	2.0	62
273	Strategies for the application of biomarkers for risk assessment and efficacy in breast cancer chemoprevention trials. Journal of Cellular Biochemistry, 1993, 53, 37-43.	1.2	7
274	Present Status of Anthracyclines in the Adjuvant Treatment of Breast Cancer. Drugs, 1993, 45, 10-19.	4.9	24
275	Complications associated with indwelling catheters. Medical and Pediatric Oncology, 1992, 20, 22-25.	1.0	13
276	Clinical course of patients with breast cancer with ten or more positive nodes who were treated with doxorubicin-containing adjuvant therapy. Cancer, 1992, 69, 448-452.	2.0	63
277	A randomized trial of two dosage schedules of mitomycin C in advanced breast carcinoma. Cancer, 1992, 69, 476-481.	2.0	22
278	Feasibility of breast-conservation surgery after induction chemotherapy for locally advanced breast carcinoma. Cancer, 1992, 69, 2849-2852.	2.0	238
279	Ki-67 immunostaining in node-negative stage I/II breast carcinoma. Significant correlation with prognosis. Cancer, 1991, 68, 549-557.	2.0	161
280	Radiotherapy enhances the toxicity of aminoglutethimide. Medical and Pediatric Oncology, 1990, 18, 162-164.	1.0	1
281	Is chemotherapy effective in reducing the local failure rate in patients with operable breast cancer?. Cancer, 1990, 65, 394-399.	2.0	57
282	Pregnancy and offspring after adjuvant chemotherapy in breast cancer patients. Cancer, 1990, 65, 847-850.	2.0	120
283	Trilostane with hydrocortisone in treatment of metastatic breast cancer. Breast Cancer Research and Treatment, 1989, 13, 117-121.	1.1	9
284	Ductal carcinoma-in-situ of the breast: Fine-needle aspiration cytology of 12 cases. Diagnostic Cytopathology, 1989, 5, 371-377.	0.5	33
285	The Role of Serum CEA as a Prognostic Indicator in Stage II and III Breast Cancer Patients Treated With Adjuvant Chemotherapy. Cancer, 1989, 63, 828-835.	2.0	21
286	5-fluorouracil rechallenge by protracted infusion in refractory breast cancer. Cancer, 1989, 64, 793-797.	2.0	46
287	Sequential cyclic combined hormonal therapy for metastatic breast cancer. Cancer, 1989, 64, 1002-1006.	2.0	13
288	Role of adjuvant chemotherapy in male breast cancer. Cancer, 1989, 64, 1583-1585.	2.0	118

#	Article	IF	Citations
289	Angiosarcoma arising in an irradiated breast. A case report and review of the literature. Cancer, 1989, 64, 2214-2216.	2.0	61
290	Ten-Year Results of FAC Adjuvant Chemotherapy Trial in Breast Cancer. American Journal of Clinical Oncology: Cancer Clinical Trials, 1989, 12, 123-128.	0.6	71
291	Adjuvant therapy of breast cancer with or without additional treatment with alternate drugs. Cancer, 1988, 62, 2098-2104.	2.0	25
292	Sequential multiagent chemotherapy incorporating cisplatin, doxorubicin, and cyclophosphamide in the treatment of metastatic breast cancer. Cancer, 1988, 62, 2105-2110.	2.0	8
293	Management of stage III primary breast cancer with primary chemotherapy, surgery, and radiation therapy. Cancer, 1988, 62, 2507-2516.	2.0	472
294	Mitoxantrone, cyclophosphamide, and fluorouracil in metastatic breast cancer unresponsive to hormonal therapy. Cancer, 1987, 59, 1992-1999.	2.0	12
295	Chemotherapy with mitoxantrone in combination with continuous infusion vinblastine for metastatic breast cancer. Cancer, 1987, 60, 1724-1728.	2.0	3
296	Combined antiestrogen and cytotoxic therapy with pseudomonas vaccine immunotherapy for metastatic breast cancer a prospective, randomized trial. Cancer, 1987, 60, 2596-2604.	2.0	15
297	Trioxifene mesylate in the treatment of advanced breast cancer. Cancer, 1986, 57, 40-43.	2.0	22
298	Clinical course of breast cancer patients with osseous metastasis treated with combination chemotherapy. Cancer, 1986, 58, 2589-2593.	2.0	120
299	A comparative study of bisantrene given by two dose schedules in patients with metastatic breast cancer. Cancer Chemotherapy and Pharmacology, 1986, 18, 157-61.	1.1	4
300	Oral medroxyprogesterone acetate in the treatment of metastatic breast cancer. Breast Cancer Research and Treatment, 1985, 5, 321-326.	1.1	44
301	Regulation of breast tumor growth by high dose estrogen is independent of the presence of estrogen receptors. Breast Cancer Research and Treatment, 1985, 6, 237-240.	1.1	8
302	A comparative randomized trial of vinca alkaloids in patients with metastatic breast carcinoma. Cancer, 1985, 55, 337-340.	2.0	44
303	Improved survival of patients with metastatic breast cancer receiving combination chemotherapy. Comparison of consecutive series of patients in 1950s, 1960s, and 1970s. Cancer, 1985, 55, 341-346.	2.0	84
304	Five-day continuous-infusion vinblastine in the treatment of breast cancer. Cancer, 1985, 56, 225-229.	2.0	47
305	A comparative study of PALA, PALA plus 5-FU, and 5-FU in advanced breast cancer. Cancer, 1985, 56, 1320-1324.	2.0	9
306	Doxorubicin-induced congestive heart failure in adults. Cancer, 1985, 56, 1361-1365.	2.0	114

#	Article	IF	Citations
307	Adjuvant chemotherapy with fluorouracil, doxorubicin, and cyclophosphamide, with or without Bacillus Calmette-Guerin and with or without irradiation in operable breast cancer a prospective randomized trial. Cancer, 1984, 53, 384-389.	2.0	73
308	Tumor-associated fever in breast cancer. Cancer, 1984, 53, 1596-1599.	2.0	13
309	Combination chemotherapy of metastatic breast carcinoma with cyclophosphamide, adriamycin, and peptichemio. Cancer, 1984, 53, 1836-1840.	2.0	4
310	Combination chemotherapy for metastatic breast cancer with fluorouracil, adriamycin, cyclophosphamide, and methotrexate. Journal of Surgical Oncology, 1984, 26, 205-207.	0.8	1
311	Analysis of the Antitumor Agent Bay i 7433 (Copovithane) in Plasma and Urine by High Performance Liquid Chromatography. Journal of Liquid Chromatography and Related Technologies, 1984, 7, 159-166.	0.9	1
312	Response of metastatic breast cancer to tamoxifen withdrawal: Report of a case. Journal of Surgical Oncology, 1983, 22, 45-46.	0.8	27
313	Spontaneous regression of breast carcinoma: Follow-up report and literature review. Journal of Surgical Oncology, 1982, 19, 22-24.	0.8	15
314	Peptichemio versus melphalan (L-PAM) in advanced breast cancer. Cancer, 1982, 49, 1767-1770.	2.0	6
315	Treatment for meningeal carcinomatosis in breast cancer. Cancer, 1982, 50, 219-222.	2.0	93
316	Management of inflammatory carcinoma of breast with combined modality approachâ€”an update. Cancer, 1981, 47, 2537-2542.	2.0	72
317	Management of breast cancer patients failing adjuvant chemotherapy with adriamycin-containing regimens. Cancer, 1981, 47, 2798-2802.	2.0	67
318	Combination chemotherapy for breast cancer metastatic to bone marrow. Cancer, 1981, 48, 227-232.	2.0	10
319	Response to hormonal therapy as a prognostic factor for metastatic breast cancer treated with combination chemotherapy. Cancer, 1980, 46, 438-445.	2.0	22
320	Combined chemoimmunotherapy for advanced breast cancer.A comparison of BCG and levamisole. Cancer, 1979, 43, 1112-1122.	2.0	33
321	Combination chemoimmunotherapy of metastatic breast cancer with 5-fluorouracil, adriamycin, cyclophosphamide, and BCG. Cancer, 1979, 43, 1225-1233.	2.0	61
322	Bone marrow metastases without cortical bone involvement in breast cancer patients. Cancer, 1979, 44, 196-198.	2.0	23
323	Combination chemotherapy with vincristine and methotrexate for advanced refractory breast cancer. Cancer, 1979, 44, 32-34.	2.0	7
324	Ftorafur, adriamycin, cyclophosphamide and bcg in the treatment of metastatic breast cancer. Cancer, 1979, 44, 398-405.	2.0	19

#	Article	IF	Citations
325	The natural history of breast cancer patients with brain metastases. Cancer, 1979, 44, 1913-1918.	2.0	279
326	Combination chemoimmunotherapy of metastatic breast cancer with 5-fluorouracil, adriamycin, cyclophosphamide, and BCG. Cancer, 1979, 44, 1955-1962.	2.0	25
327	Combined chemoimmunotherapy and radiation therapy of inflammatory breast carcinoma. Journal of Surgical Oncology, 1979, 11, 325-332.	0.8	35
328	Adjuvant chemoimmunotherapy following regional therapy for isolated recurrences of breast cancer (stage IV NED). Journal of Surgical Oncology, 1979, 12, 27-40.	0.8	48
329	Chemoimmunotherapy with or without oophorectomy in premenopausal patients with advanced breast cancer. Journal of Surgical Oncology, 1979, 12, 333-341.	0.8	2
330	Intensive postoperative chemoimmunotherapy for patients with stage II and stage III breast cancer. Cancer, 1978, 41, 1064-1075.	2.0	65
331	Adriamycin and 1-(2-Chlorethyl)-3-Cyclohexyl-1-Nitrosourea (CCNU) in the treatment of metastatic breast cancer. Cancer, 1978, 41, 1235-1239.	2.0	16